Compare UA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | OGN |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | UA | OGN |
|---|---|---|
| Price | $4.34 | $7.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | 4.7M | ★ 4.7M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 1.15% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $5,049,070,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.54 | N/A |
| P/E Ratio | ★ N/A | $3.65 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.95 | $6.18 |
| 52 Week High | $7.85 | $17.23 |
| Indicator | UA | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 44.78 |
| Support Level | $4.07 | $6.75 |
| Resistance Level | $4.44 | $7.14 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.10 | 40.72 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.